Percepta Genomic Sequencing Classifier May Improve Clinical Decision Making Regarding Lung Nodules
Researchers present data that demonstrate how the Percepta Genomic Sequencing Classifier can enhance care decisions regarding lung nodules.
Researchers present data that demonstrate how the Percepta Genomic Sequencing Classifier can enhance care decisions regarding lung nodules.
Researchers assessed the associations between patients’ understanding of their prognosis and their end-of-life care decisions.
Researchers present data on a program designed to increase completion rates among patients with suspicious lung nodules on screening CT.
Researchers present their prediction model for assessing risk of brain metastases in patients with non-small cell lung cancer.
Younger patients had a significant decrease in sleep time on days they received dexamethasone.
Black patients were more likely than White patients to have distant metastases.
Improvements were seen in event-free and overall survival.
The combination improved invasive disease-free survival and distant relapse-free survival.
The 1-year overall survival rate was 71%.
Researchers sought to determine whether a combination therapy with bortezomib-augmented ASCT would have efficacy in patients with ultra high-risk multiple myeloma or plasma cell leukemia.